Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Age-specific prostate-specific antigen: a reassessment

R Etzioni1, Y Shen, J C Petteway

  • 1Program in BiostatisticS, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

The Prostate. Supplement
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply by Authors.

The Journal of urology·2019
Same author

Deriving benefit of early detection from biomarker-based prognostic models.

Biostatistics (Oxford, England)·2012
Same author

Prostate cancer and computer models: Background, limitations, and potential.

Urologic oncology·2011
Same author

Clinical Evidence: Non-metastatic prostate cancer.

The Western journal of medicine·2008
Same author

Modern brachytherapy for localized prostate cancers: the northwest hospital (Seattle) experience.

Reviews in urology·2006
Same author

Letter from the editors of reviews in urology.

Reviews in urology·2006

Screening for prostate cancer using a prostate-specific antigen (PSA) cutoff of 4.0 ng/ml for all ages appears more efficient than age-specific bounds. This method identifies more cancer cases, potentially leading to greater survival benefits per case.

Area of Science:

  • Urology
  • Oncology
  • Public Health

Background:

  • Prostate cancer screening commonly utilizes prostate-specific antigen (PSA) testing.
  • Current screening protocols often employ age-specific PSA thresholds.
  • The efficacy of a uniform PSA cutoff (4.0 ng/ml) versus age-specific bounds requires comparative analysis for survival benefits.

Purpose of the Study:

  • To compare the expected survival benefits of prostate cancer screening using a uniform PSA cutoff of 4.0 ng/ml against age-specific PSA bounds.
  • To evaluate the efficiency of different PSA screening strategies in detecting prostate cancer and impacting patient survival.

Main Methods:

  • Decision analysis modeling was employed to simulate cancer yield and survival outcomes for both screening strategies.
  • Data on cancer yields and positive predictive values were derived from ultrasound-guided biopsy series.

Related Experiment Videos

  • Survival models accounted for screen-detected localized and non-localized prostate cancer cases, considering lead time bias.

    • Main Results:

    • Screening with a PSA cutoff of 4.0 ng/ml detected significantly more prostate cancer cases compared to age-specific PSA bounds.
    • The average years of life saved per subject screened were comparable between the two methods.
    • However, the average years of life saved per identified cancer case appeared potentially greater with the PSA > 4.0 ng/ml cutoff.

    Conclusions:

    • A uniform PSA cutoff of 4.0 ng/ml is more efficient in identifying men with prostate cancer within a screening cohort.
    • This strategy translates to a potentially greater expected survival benefit per cancer case detected.
    • The findings suggest that a universal PSA threshold may optimize prostate cancer screening outcomes.